Navigation Links
Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS
Date:12/10/2010

icant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration (FDA) for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Only the FDA can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the FDA-approved labeling for the products, and not the information discussed in this news release.

About AmgenAmgen discovers, develops, manufactures and delivers innovative human therapeutics.  A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient.  Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses.  With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.  To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

(i)  Cleeland CS, et al. Pain and its treatment in outpatients with metastatic cancer.N Eng J Med. 1994: 330:592-596.

(ii)  Janjan N.Bone metastases: Approaches to management. Semin Oncol. 2001: 28:28-34.

(iii)  Schulman KL, Kohles J. Economic burden
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Amgen to Present at Deutsche Banks 2010 BioFEST
2. Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting
3. Amgen Foundation and Ashokas Changemakers Announce Finalists in Patients
4. Choices
5. Empowerment Competition
6. Amgen, Pfizer, and World-Class Professional Golfer Phil Mickelson Announce Partnership
7. Amgen Foundation Awards $4.5 Million Grant to MLA Partner Schools to Invest in LAs Promise
8. Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year
9. Amgen Announces Webcast of 2010 Third Quarter Financial Results
10. Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today
11. Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 BD Biosciences, a segment ... ), a leading global medical technology company, today announced the ... the latest in its line of high-performance research flow cytometers. ... high-performance multicolor analysis with the most compact footprint in its ... and a height of 30" (76.2 cm). Recognizing that space ...
(Date:6/19/2013)... -- Today leading web researchers Change Sciences Group ( ... sites for usability, engagement, and conversion. The rankings are ... compares how people experience sites with competitors and with ... top three performers are easier to use, more engaging ... have usability problems, lack aspects of design that compel ...
(Date:6/19/2013)... 2013   Life Technologies Corporation (NASDAQ: ... granting Suzhou Ribo Life Sciences (Ribo) the exclusive ... China using Life,s Invivofectamine® ... molecules in combination with Invivofectamine® Rx to create ... with high unmet medical need in the Chinese ...
Breaking Medicine Technology:New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2Sunovion tops new Change Sciences User Experience Rankings for Pharmaceutical Industry while McNeil-PPC ranks worst overall 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4
... Mass., Nov. 13 Hologic, Inc.,(Nasdaq: HOLX ... premium,diagnostics, medical imaging systems and surgical products dedicated ... the results of the,Cervista HPV high-risk pivotal clinical ... review by the FDA in the U.S. and ...
... YORK, Nov. 12 A new study being,published in ... the,question, what causes Parkinson,s disease?, One of the ... is what causes the sensitive cells in the brain ... been especially difficult,because there are two nearly identical types ...
Cached Medicine Technology:Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 2Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 3Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 4A Window Into Parkinson's Disease 2
(Date:6/19/2013)... Quapaw, OK (PRWEB) June 19, 2013 ... of Companies, including RWI Benefits, LLC, Native Care ... The National Association of Health Underwriters’ (NAHU) new ... Affordable Care Act (PPACA). This continuing education course ... states, and Roberson will receive eleven education credits ...
(Date:6/19/2013)... According to a June 17, 2013 Allure ... is not uncommon for a person to suffer from a ... is likely to forget to reapply sunscreen properly and end ... and itchy. When this occurs, it is essential to act ... people do not realize that milk contains proteins, fats, and ...
(Date:6/19/2013)... In a major international study led by researchers at ... targeted therapy ibrutinib continues to show remarkable promise for ... (MCL). , The most recent interim findings of the ... New England Journal of Medicine . Previous interim ... American Society of Hematology Annual Meeting and Exposition. ...
(Date:6/19/2013)... Pa. (June 19, 2013) The results of three ... of Neurosurgery , official journal of the ... published by Lippincott Williams & Wilkins , a ... study indicates that continuous "machine learning" using artificial neural ... in patients with advanced brain cancers. Another study in ...
(Date:6/19/2013)... reveals significant disparities between minority and white clients ... programs. Moreover, these disparities vary widely from state ... for most states there,s something amiss," says Stephan ... "There are strong racial and ethnic disparities for ... treatment programs successfully, and those disparities are something ...
Breaking Medicine News(10 mins):Health News:RWI Benefits, LLC Becomes PPACA Certified 2Health News:Skin Care – How to treat Sunburn 2Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3
... Dec. 1 Acuo Technologies(R), developers,of high-performance software ... services, today announced the contracting with Rush,University ... new vendor neutral archiving,solution which becomes the basis ... archiving solution is based on the Acuo Technologies ...
... In recognition of World AIDS Day, Charlotte Bobcats, Emeka Okafor, will ... One Million African Lives Initiative (OMALI), a program of the Safe ... is to save one million lives in Africa by 2011 by ... , , OMALI will be ...
... TOMS Shoes, the philanthropic,footwear company, has launched a ... and Give More this holiday season. For 30,days, from ... to help give 30,000 pairs of shoes to children ... preventable by wearing shoes. By,purchasing a pair of shoes ...
... , , ANN ARBOR, ... pajamas or a video game are all quick and easy gifts to ... not give something more healthy and beneficial to a loved one? Why ... Staying healthy around the holidays can be challenging, and this ...
... Dec. 1 TorreyPines Therapeutics, Inc.,(Nasdaq: ... administration of NGX426, an,AMPA/kainate-type glutamate receptor antagonist, ... hyperalgesia (abnormally increased,pain state) and allodynia (pain ... compared to placebo following intradermal injections of ...
... Horvath, D.V.M., as Vice President of Preclinical Sciences and ... , CAMBRIDGE, Mass., Dec. ... Mass.-based executive team with the appointment of Jeffrey T. ... announced the additions of Christopher Horvath, D.V.M., as vice ...
Cached Medicine News:Health News:Acuo Technologies Announces Vendor Neutral Archiving Contract With Rush University Medical Center 2Health News:Acuo Technologies Announces Vendor Neutral Archiving Contract With Rush University Medical Center 3Health News:In Recognition of WORLD AIDS DAY, Charlotte Bobcats' Power Forward, Emeka Okafor, Launches Mobile Texting Campaign in Support of the One Million African Lives Initiative 2Health News:TOMS Shoes Embarks on a Holiday Mission: Give 30,000 Pairs in 30 Days! 2Health News:Giving the Gift of Health This Holiday Season 2Health News:Giving the Gift of Health This Holiday Season 3Health News:Giving the Gift of Health This Holiday Season 4Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 2Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 3Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 4Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 5Health News:Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer 2Health News:Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer 3
... to provide excellent protection and ease of ... being closer to an adhesive in molecular ... CoEase to maintain viscosity at high shear ... worlds for superb performance during capsulorhexis, phaco, ...
... viscosurgical device is a cohesive ... high molecular weight, high pseudoplasticity, ... provides excellent space maintenance, facilitates ... removed. It is available in ...
... VISUCAM DigitalCameras permit fundus imaging and ... operation without any need for eyepieces ... findings. Image recording and display is ... utilizes the ophthalmoscope principle of modern ...
... The ARIS A utomated R ... revolutionary, patented technology which provides rapid and automated ... allows eye care professionals to screen and ... in less time and at ...
Medicine Products: